Given the lack of effective therapies for patients with neutrophilic asthma and the availability of rIFN-γ as an FDA-approved treatment for chronic granulomatous disease and severe malignant osteopetrosis,76 we explored IFN-γ as a potential opportunity to mitigate neutrophilic allergic airway disease. The gene discussed is IFNG; the disease is chronic granulomatous disease.